✦ LIBER ✦

High-dose chemotherapy and blood stem cell autografts for children with first relapsed acute lymphoblastic leukemia: A pilot study of the children's cancer and leukemia study group of Japan (CCLSG)

✍ Scribed by Takaue, Yoichi ;Watanabe, Arata ;Murakami, Tatsuo ;Watanabe, Tsutomu ;Kawano, Yoshifumi ;Kuroda, Yasuhiro ;Matsushita, Takeji ;Kikuta, Atsushi ;Kosaka, Yoshiyuki ;Kudo, Toru ;Shimizu, Hiroyuki ;Koizumi, Shoichi ;Fujimoto, Takeo

Publisher: John Wiley and Sons
Year: 1994
Tongue: English
Weight: 508 KB
Volume: 23
Category: Article
ISSN: 0098-1532
DOI: 10.1002/mpo.2950230105

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

This study was performed to determine the value of high‐dose chemotherapy and peripheral blood stem cell autografts (PBSCT) in the treatment of children with first relapsed acute lymphoblastic leukemia (ALL). Eighteen children underwent PBSCT during the second complete remission (CR) and had a minimum 10 month follow‐up. The median age of the patients was 11 yr (range, 2–17 yr). Fifteen patients received the “MCVAC” regimen, one received high‐dose MCNU + busulfan therapy, one received high‐dose melphalan + VP‐16, and one received melphalan + carboplatin + cytosine arabinoside + MCNU. None of these regimens included total body irradiation. Eight patients developed recurrence of the disease at 1 to 19 mo (median, 3 mo) after PBSCT. Patients in whom the first relapse occurred sooner, that is, within 16 mo of initial therapy, tended to have a better survival rate than those who developed relapse after 30 mo (six of seven survived versus four of 11; not significant). Although the preliminary data provided little conclusive information, it did suggest that incorporation of PBSCT in the salvage protocol of relapsed childhood ALL can be justified. © 1994 Wiley‐Liss, Inc.

📜 SIMILAR VOLUMES

Prognosis and treatment after relapse of

Prognosis and treatment after relapse of acute lymphoblastic leukemia and non-Hodgkin's lymphoma: 1985: A report from the childrens cancer study group

✍ W. Archie Bleyer; Harland Sather; G. Denman Hammond 📂 Article 📅 1986 🏛 John Wiley and Sons 🌐 English ⚖ 487 KB 👁 3 views

Treatment of high-risk acute lymphoblast

Treatment of high-risk acute lymphoblastic leukemia in children using the AL851 and ALHR88 protocols: A report from the Kyushu-Yamaguchi children cancer study group in Japan

✍ Matsuzaki, Akinobu; Ishii, Eiichi; Okamura, Jun; Eguchi, Haruhiko; Yoshida, Nobu 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 770 KB

A total of 125 children, who were diagnosed as having high-risk acute lymphoblastic leukemia (ALL), were treated with two consecutive protocols designated as AL851 (1985( -1988( ) and ALHR88 (1988( -1990)). All patients received induction therapy consisting of vincristine (VCR), prednisolone (PSL),

DNA index and %S-phase cells determined

DNA index and %S-phase cells determined in acute lymphoblastic leukemia of children: A report from studies ALL V, ALL VI, and ALL VII (1979–1991) of the dutch childhood leukemia study group and the Netherlands workgroup on cancer genetics and cytogenetics

✍ Smets, L. A. ;Slater, R. ;van Wering, E. R. ;van der Does-van den Berg, A. ;Hart 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 834 KB

## Abstract DNA per cell content was routinely recorded by single‐parameter flow cytometry in leukemic blasts from 473 children with acute lymphoblastic leukemia (ALL), enrolled in national studies ALL V, VI, and VII (1979–1991) of the Dutch Childhood Leukemia Study Group. The parameters bonemarrow

Hematopoietic stem cell transplantation

Hematopoietic stem cell transplantation (HSCT) with a conditioning regimen of busulfan, cyclophosphamide, and etoposide for children with acute myelogenous leukemia (AML): A phase I study of the pediatric blood and marrow transplant consortium

✍ Sandler, E.S. ;Hagg, R. ;Coppes, M.J. ;Mustafa, M.M. ;Gamis, A. ;Kamani, N. ;Wal 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 157 KB 👁 3 views

Effective preventive central nervous sys

Effective preventive central nervous system therapy with extended triple intrathecal therapy and the modified ALL-BFM 86 chemotherapy program in an enlarged non-high risk group of children and adolescents with non-B-cell acute lymphoblastic leukemia : The ISRAEL National Study report

✍ Batia Stark; Rivka Sharon; Gideon Rechavi; Dina Attias; Ami Ballin; Gabriel Civi 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 145 KB 👁 2 views

BACKGROUND. Preventive cranial radiotherapy (CRT) in childhood acute lymphoblastic leukemia (ALL), although effective, may be associated with neurologic sequelae and second malignancies. Attempts to replace CRT with intensified intrathecal therapy (IT) have shown promise in lower risk subgroups. In

Excellent therapeutic efficacy and minim

Excellent therapeutic efficacy and minimal late neurotoxicity in children treated with 18 grays of cranial radiation therapy for high-risk acute lymphoblastic leukemia : A 7-year follow-up study of the dana-farber cancer institute consortium protocol 87-01

✍ Deborah P. Waber; Brenda L. Shapiro; Sarah C. Carpentieri; Richard D. Gelber; Gu 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 89 KB 👁 3 views

## Background: In the current study, the authors evaluated late neuropsychologic effects 7 years after diagnosis and the long-term survival in a cohort of patients treated for high-risk childhood acute lymphoblastic leukemia (all) with cranial radiation therapy. efficacy and toxicity were evaluated